TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Harrow Health ( (HROW) ) has provided an announcement.
On November 17, 2025, Harrow, Inc. completed its acquisition of Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company specializing in non-opioid, non-IV sedation therapies for medical procedures. This strategic acquisition expands Harrow’s portfolio and positions it to enter the multi-billion-dollar procedural sedation and anxiety market with products like MELT-300, a sublingual sedation therapy that has shown promise in clinical trials. The acquisition is expected to enhance Harrow’s market positioning by offering innovative sedation options that reduce opioid exposure and improve patient experiences across various medical specialties.
The most recent analyst rating on (HROW) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
Harrow Health’s overall stock score is primarily influenced by its strong revenue growth and strategic product performance, as highlighted in the earnings call. However, significant financial risks due to high leverage and negative profitability, along with valuation concerns, weigh down the score. Technical indicators suggest a neutral to slightly bearish outlook.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products addressing various ocular conditions such as dry eye disease, cataracts, and glaucoma. The company is committed to delivering safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes.
Average Trading Volume: 732,261
Technical Sentiment Signal: Buy
Current Market Cap: $1.51B
Find detailed analytics on HROW stock on TipRanks’ Stock Analysis page.